Tryton Medical announces implantation of Tryton stent for the first time in Portugal and Austria

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the Tryton^® stent has been implanted for the first time in Portugal and Austria.

“The rapid adoption of the Tryton Side Branch Stent is extremely gratifying. The system has now been implanted in more than 750 European patients”

Francisco Pereira Machado, M.D., of Hospital da Luz in Lisbon performed the first implant in Portugal.

“The Tryton Side Branch Stent is a simple approach to secure and dilate the side branch with optimal scaffolding of its ostium. Its use makes the placement and deployment of the main vessel stent easy,” said Dr. Machado. “When there is involvement of both the main vessel and the side branch, and when, for any reason, you choose to go for two stents, think of dedicated stents. Keep it simple.”

Olev Luha, M.D., Ph.D., from the LKH University Hospital in Graz was the first to use the Tryton Side Branch Stent in Austria and has implanted four Tryton stents during four different procedures.

"I am pleased to have had the opportunity to start using the Tryton Side Branch Stent. The Tryton is easy to use and allows for a predictable treatment of bifurcation lesions, which are some of the most complex lesions that we get to treat. Going forward, I will use the Tryton Side Branch Stent in my daily practice," said Dr. Luha.

“The rapid adoption of the Tryton Side Branch Stent is extremely gratifying. The system has now been implanted in more than 750 European patients,” said J. Greg Davis, president and CEO of Tryton Medical. “We are very pleased that the Tryton^® stent is now available in Portugal and Austria, giving physicians in those countries a dedicated strategy for these difficult-to-treat areas of disease, which are a frequent occurrence – approximately one in every four cases.”